肺腺癌中的甲素L:通过多个OMIC视角的预后意义和免疫治疗反应
Jianming Lu1, Jiaqi Liang2, Gang Xiao1,3
1Center for Medical Research on Innovation and Translation, Institute of Clinical Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Cancer informatics
|December 17, 2024
概括
甲素L (CTSL) 是肺腺癌 (LUAD) 的一个有前途的预后生物标志物. 高CTSL表达与晚期疾病和低生存率相关,表明其作为治疗点的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物标志物发现发现
背景情况:
- 肺腺癌 (LUAD) 的转移和复发率很高,导致患者的预后不佳.
- 迫切需要精确的生物标志物来预测LUAD患者的结果.
研究的目的:
- 确定和验证Cathepsin L (CTSL) 作为肺腺癌的精确预后生物标志物.
- 研究CTSL在LUAD进展中的功能作用.
主要方法:
- 来自TCGA和GEO的RNA测序和突变数据的基于多中心的分析.
- 使用CRISPR/Cas9技术对CTSL进行功能评估.
- 在当地的LUAD队列中对CTSL蛋白表达的免疫组织化学 (IHC) 验证.
主要成果:
- 较高的CTSL表达与晚期的LUAD阶段和较差的整体存活率显著相关.
- 在LUAD细胞系中,CTSL淘汰抑制了瘤增殖.
- 通过血管新生和TGF-β信号传递,CTSL促进瘤的进展,同时抑制细胞亡和DNA修复.
结论:
- CTSL是LUAD的关键预后生物标志物.
- 在促进瘤进展方面,CTSL的作用突显了其作为LUAD患者治疗标和预后标记物的潜力.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K


